SPOTLIGHT: Biocon denies buyout report


Biocon caused a stir this morning after an Indian financial newspaper claimed the country's biggest biotech was nearing a $400 million buyout deal with a U.S. company. But Biocon executives moved quickly to squelch the story, saying the report was "speculative" and inaccurate. Report

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.